Agentix (AGTX) Cash from Financing Activities (2015 - 2026)
Agentix's (AGTX) quarterly Cash from Financing Activities came in at $10100.0 in Q4 2025, down 59.6% YoY from $25000.0 in Q4 2024, and up 2785.71% on a QoQ basis from $350.0 in Q3 2025.
Agentix (AGTX) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Agentix (AGTX) has 10 years of Cash from Financing Activities data on file, last reported at $10100.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 59.6% year-over-year to $10100.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $110450.0 (up 10.45% YoY) and the FY2026 annual result came in at $110450.0, up 10.45% from the prior year.
- Cash from Financing Activities improved to $10100.0 in Q4 2025, from $350.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $100000.0 in Q2 2025 to a low of -$50000.0 in Q3 2023.
- A 5-year average of $34532.1 and a median of $44000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 200.0% — and 2025, when it soared 400.0%.
- Tracing AGTX's Cash from Financing Activities over 5 years: stood at $80000.0 in 2021, then plunged by 37.5% to $50000.0 in 2022, then changed by 0.0% to $50000.0 in 2023, then slumped by 50.0% to $25000.0 in 2024, then slumped by 59.6% to $10100.0 in 2025.
- The last three Cash from Financing Activities figures came in at $10100.0 (Q4 2025), $350.0 (Q3 2025), and $100000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | 26,250.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26,250.00 |
| Jun 30, 2026 | 26,250.00 |
| Dec 31, 2025 | 10,100.00 |
| Dec 31, 2025 | 10,100.00 |
| Sep 30, 2025 | 350.00 |
| Sep 30, 2025 | 350.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Dec 31, 2023 | 50,000.00 |
| Dec 31, 2023 | 50,000.00 |